ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Speciality Medicines Limited has scheduled a board meeting on November 12, 2026. The board will consider and approve unaudited standalone financial results for the half-year ended September 30, 2026.
Speciality Medicines Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31.
Speciality Medicines Limited conducted its 5th Annual General Meeting on September 28, 2026. Shareholders considered the adoption of FY26 audited financial statements and the re-appointment of Director Sumit Goyani.
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.
Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.
Speciality Medicines Limited has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency to enhance its investor relations and communication efforts.
Speciality Medicines Ltd reported revenue from operations of ₹44.8 Cr (+45.5% YoY) and net profit of ₹8.2 Cr (+203.7% YoY) for H2 FY26.
Speciality Medicines Ltd reported its audited standalone financial results for the year ended March 31, 2026. The company also confirmed full utilization of its IPO proceeds.
Speciality Medicines Ltd scheduled a board meeting for May 28, 2026, to approve audited financial results. The trading window remains closed for insiders until May 30.